Selective Serotonin Reuptake Inhibitors for Stroke Recovery

Therapies Wednesday, March 6th, 2013

STROKEAHA: January 29, 2013

Each year, about 16 million people in the world experience a first-ever stroke. Of these, about 5.7 million die and another 5 million remain disabled.1 Although there are effective treatments that restore brain perfusion and minimize complications and recurrent stroke, there is no treatment proven to facilitate neurological recovery after stroke.

A recent small trial demonstrated that the selective serotonin reuptake inhibitor (SSRI) fluoxetine, commonly used to treat depression, improved motor recovery and reduced dependency after stroke when given to people without depression.2 Experimental studies reporting neurogenic and neuroprotective effects of SSRIs3,4 provide a plausible mechanism of action. Read more

National Minority Quality Forum Clinical Trial Engagement Network Map Childhood Obesity MapHIV Z-Atlas: Peripheral Arterial Disease Atlas Map Lung Cancer Index Z-Atlas: Chronic Kidney Disease AFIB Index Cardiometabolic Health Aliance Minority Diabetes Coalition U.S. Diabetes Index County Edition U.S. Diabetes Index Research Edition Medicare Index Medicare Index Stroke Edition About The Minority Stroke Working Group Hepatitis C Disease Index Lead Risk Index Map MRSA StrokePAD Minority Index The South Texas Diabetes Initiative Minority Stroke Consortium YouTube NMQF Videos IPAB Action Center National Health Index

© 2011 National Minority Quality Forum, Inc. All Rights Reserved.